Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL

Vascular Pharmacology - Tập 82 - Trang 30-40 - 2016
Emma Harper1, Hannah Forde2,1, Colin Davenport2, Keith D. Rochfort3, Diarmuid Smith2, Philip M. Cummins1
1School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
2Department of Academic Endocrinology, Beaumont Hospital, Dublin 9, Ireland
3Conway Institute, University College Dublin, Dublin 4, Ireland

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rubin, 2004, Vascular calcification and osteoporosis — the nature of the nexus, J Clin Endocrinol Metab, 89, 4243, 10.1210/jc.2004-1324

Demer, 1991, Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation, Circulation, 83, 2083, 10.1161/01.CIR.83.6.2083

Proudfoot, 2001, Biology of calcification in vascular cells: intima versus media, Herz, 26, 245, 10.1007/PL00002027

Lehto, 1996, Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus, Arterioscler Thromb Vasc Biol, 16, 978, 10.1161/01.ATV.16.8.978

Trouvin, 2010, Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss, Clin Interv Aging, 5, 345

Ducy, 2000, The osteoblast: a sophisticated fibroblast under central surveillance, Science, 289, 1501, 10.1126/science.289.5484.1501

Teitelbaum, 2000, Bone resorption by osteoclasts, Science, 289, 1504, 10.1126/science.289.5484.1504

Kearns, 2008, Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease, Endocr Rev, 29, 155, 10.1210/er.2007-0014

Boyce, 2007, Biology of RANK, RANKL, and osteoprotegerin, Arthritis Res Ther, 9, S1, 10.1186/ar2165

Wada, 2006, RANKL–RANK signalling in osteoclastogenesis and bone disease, Trends Mol Med, 12, 17, 10.1016/j.molmed.2005.11.007

Myers, 1999, Expression of functional RANK on mature rat and human osteoclasts, FEBS Lett, 463, 295, 10.1016/S0014-5793(99)01650-6

Atkins, 2006, RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone, J Bone Miner Res, 21, 1339, 10.1359/jbmr.060604

Luan, 2012, Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin, J Immunol, 189, 245, 10.4049/jimmunol.1103387

Liu, 2010, Structural and functional insights of RANKL–RANK interaction and signaling, J Immunol, 184, 6910, 10.4049/jimmunol.0904033

Ikeda, 2001, Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus, Endocrinology, 142, 1419, 10.1210/endo.142.4.8070

Lacey, 2012, Bench to bedside: elucidation of the OPG-RANK–RANKL pathway and the development of denosumab, Nat Rev Drug Discov, 11, 401, 10.1038/nrd3705

Nakashima, 2011, Evidence for osteocyte regulation of bone homeostasis through RANKL expression, Nat Med, 17, 1231, 10.1038/nm.2452

Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852

Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X

Hofbauer, 2004, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases, JAMA, 292, 490, 10.1001/jama.292.4.490

Yasuda, 1998, Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro, Endocrinology, 139, 1329, 10.1210/endo.139.3.5837

Yamaguchi, 1998, Characterization of structural domains of human osteoclastogenesis inhibitory factor, J Biol Chem, 273, 5117, 10.1074/jbc.273.9.5117

Venuraju, 2010, Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity, J Am Coll Cardiol, 55, 2049, 10.1016/j.jacc.2010.03.013

Demer, 2001, Cholesterol in vascular and valvular calcification, Circulation, 104, 1881, 10.1161/circ.104.16.1881

Orimo, 2010, The mechanism of mineralization and the role of alkaline phosphatase in health and disease, J Nippon Med Sch, 77, 4, 10.1272/jnms.77.4

Singh, 2012, Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function, Diabetes Res Clin Pract, 97, 158, 10.1016/j.diabres.2012.01.038

Panizo, 2009, RANKL increases vascular smooth muscle cell calcification through a RANK–BMP4-dependent pathway, Circ Res, 104, 1041, 10.1161/CIRCRESAHA.108.189001

Ross, 1999, Atherosclerosis — an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207

Cunningham, 2005, The role of shear stress in the pathogenesis of atherosclerosis, Lab Invest, 85, 9, 10.1038/labinvest.3700215

Aronson, 2002, How hyperglycemia promotes atherosclerosis: molecular mechanisms, Cardiovasc Diabetol, 1, 1, 10.1186/1475-2840-1-1

Singh, 2009, Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria?, Diabetes Res Clin Pract, 85, 258, 10.1016/j.diabres.2009.06.022

Singh, 2010, Review: endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes, Br J Diab Vasc Dis Res, 10, 71, 10.1177/1474651409355453

Luo, 1997, Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein, Nature, 386, 78, 10.1038/386078a0

Speer, 2009, Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries, Circ Res, 104, 733, 10.1161/CIRCRESAHA.108.183053

Steitz, 2001, Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers, Circ Res, 89, 1147, 10.1161/hh2401.101070

Tintut, 2006, Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification, J Invest Med, 54, 395, 10.2310/6650.2006.06019

Papadopouli, 2008, Role of OPG/RANKL/RANK axis on the vasculature, Histol Histopathol, 23, 497

Yamaguchi, 2010, Vascular calcification: mutual interaction between bone and blood vessel, Clin Calcium, 20, 1669

Bessueille, 2015, Glucose stimulates chondrocyte differentiation of vascular smooth muscle cells and calcification: a possible role for IL-1β, FEBS Lett, 589, 2797, 10.1016/j.febslet.2015.07.045

Sage, 2010, Regulatory mechanisms in vascular calcification, Nat Rev Cardiol, 7, 528, 10.1038/nrcardio.2010.115

Ndip, 2011, The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy, Diabetes, 60, 2187, 10.2337/db10-1220

Kaden, 2004, Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification, J Mol Cell Cardiol, 36, 57, 10.1016/j.yjmcc.2003.09.015

Collin-Osdoby, 2004, Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin, Circ Res, 95, 1046, 10.1161/01.RES.0000149165.99974.12

Schoppet, 2004, Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis, J Clin Endocrinol Metab, 89, 4104, 10.1210/jc.2003-031432

Gochuico, 2000, TRAIL expression in vascular smooth muscle, Am J Physiol Lung Cell Mol Physiol, 278, L1045, 10.1152/ajplung.2000.278.5.L1045

Sato, 2006, TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque, J Exp Med, 203, 239, 10.1084/jem.20051062

Emery, 1998, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J Biol Chem, 273, 14363, 10.1074/jbc.273.23.14363

Li, 2003, TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells, J Immunol, 171, 1526, 10.4049/jimmunol.171.3.1526

Kavurma, 2008, TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor, J Biol Chem, 283, 7754, 10.1074/jbc.M706927200

Secchiero, 2003, TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways, Circulation, 107, 2250, 10.1161/01.CIR.0000062702.60708.C4

Secchiero, 2004, TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells, Cell Mol Life Sci, 61, 1965, 10.1007/s00018-004-4197-6

Vitovski, 2007, Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways, J Biol Chem, 282, 31601, 10.1074/jbc.M706078200

Di Bartolo, 2011, Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification, Cardiovasc Res, 91, 537, 10.1093/cvr/cvr084

Zauli, 2004, TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF, Blood, 104, 2044, 10.1182/blood-2004-03-1196

Di Bartolo, 2013, TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL, PLoS One, 8, 10.1371/annotation/9732ca63-7532-4b92-8d6e-65c0863f25aa

Olesen, 2012, No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells, Mol Cell Endocrinol, 362, 149, 10.1016/j.mce.2012.06.004

Byon, 2011, Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages, Arterioscler Thromb Vasc Biol, 31, 1387, 10.1161/ATVBAHA.110.222547

Chasseraud, 2011, Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification, Ther Apher Dial, 15, 140, 10.1111/j.1744-9987.2010.00886.x

Corallini, 2009, Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin, Eur J Histochem, 53, 19, 10.4081/ejh.2009.e3

Eddahibi, 2006, Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia, Circulation, 113, 1857, 10.1161/CIRCULATIONAHA.105.591321

Chiu, 2009, Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis, Ann Med, 41, 19, 10.1080/07853890802186921

Osako, 2010, Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification, Circ Res, 107, 466, 10.1161/CIRCRESAHA.110.216846

Bucay, 1998, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, 12, 1260, 10.1101/gad.12.9.1260

Callegari, 2013, Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification, Arterioscler Thromb Vasc Biol, 33, 2491, 10.1161/ATVBAHA.113.301755

Callegari, 2014, Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-κB ligand and interleukin 6, J Vasc Res, 51, 118, 10.1159/000358920

Secchiero, 2006, An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction, Am J Pathol, 169, 2236, 10.2353/ajpath.2006.060398

Secchiero, 2006, Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice, Circulation, 114, 1522, 10.1161/CIRCULATIONAHA.106.643841

Di Bartolo, 2011, TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe−/− mice, Diabetologica, 54, 3157, 10.1007/s00125-011-2308-0

Zauli, 2008, TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors, J Cell Physiol, 214, 117, 10.1002/jcp.21165

Budoff, 2010, Progression of coronary artery calcium predicts all-cause mortality, JACC Cardiovasc Imaging, 3, 1229, 10.1016/j.jcmg.2010.08.018

Detrano, 2008, Coronary calcium as a predictor of coronary events in four racial or ethnic groups, N Engl J Med, 358, 1336, 10.1056/NEJMoa072100

Morrish, 2001, Mortality and causes of death in the WHO multinational study of vascular disease in diabetes, Diabetologica, 44, S14, 10.1007/PL00002934

Shao, 2010, Inflammation and the osteogenic regulation of vascular calcification: a review and perspective, Hypertension, 55, 579, 10.1161/HYPERTENSIONAHA.109.134205

Van Campenhout, 2009, Osteoprotegerin, vascular calcification and atherosclerosis, Atherosclerosis, 204, 321, 10.1016/j.atherosclerosis.2008.09.033

Di Bartolo, 2014, Regulation and function of Rankl in arterial calcification, Curr Pharm Des, 20, 5853, 10.2174/1381612820666140212205455

Reinhard, 2010, Osteoprotegerin and mortality in type 2 diabetic patients, Diabetes Care, 33, 2561, 10.2337/dc10-0858

Vik, 2011, Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study, J Thromb Haemost, 9, 638, 10.1111/j.1538-7836.2011.04222.x

O'Sullivan, 2010, Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes, Diabetes Metab Res Rev, 26, 496, 10.1002/dmrr.1109

Abedin, 2007, Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study), Am J Cardiol, 99, 513, 10.1016/j.amjcard.2006.08.064

Schoppet, 2003, Increased osteoprotegerin serum levels in men with coronary artery disease, J Clin Endocrinol Metab, 88, 1024, 10.1210/jc.2002-020775

Ziegler, 2005, Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease, Atherosclerosis, 182, 175, 10.1016/j.atherosclerosis.2005.01.042

Omland, 2008, Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes, J Am Coll Cardiol, 51, 627, 10.1016/j.jacc.2007.09.058

Higgins, 2015, Distribution of alkaline phosphatase, osteopontin, rank ligand and osteoprotegerin in calcified human carotid atheroma, Protein J, 34, 315, 10.1007/s10930-015-9620-3

Morony, 2008, Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice, Circulation, 117, 411, 10.1161/CIRCULATIONAHA.107.707380

Jung, 2010, The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM, Acta Diabetol, 47, 145, 10.1007/s00592-009-0154-z

Gaudio, 2014, Relationships between osteoprotegerin, receptor activator of the nuclear factor kB ligand and serum levels and carotid intima–media thickness in patients with type 2 diabetes mellitus, Panminerva Med, 56, 221

Rozas Moreno, 2013, Serum osteoprotegerin: bone or cardiovascular marker in type 2 diabetes males?, J Endocrinol Invest, 36, 16

Poulsen, 2011, Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus, Cardiovasc Diabetol, 10, 76, 10.1186/1475-2840-10-76

Tavintharan, 2014, Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus, Diab Vasc Dis Res, 11, 359, 10.1177/1479164114539712

Anand, 2006, The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects, J Am Coll Cardiol, 47, 1850, 10.1016/j.jacc.2005.12.054

Anand, 2007, Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers, J Am Coll Cardiol, 50, 2218, 10.1016/j.jacc.2007.08.032

Giaginis, 2012, Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis, Med Sci Monit, 18, CR597, 10.12659/MSM.883485

Poornima, 2014, Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women, Menopause, 21, 702, 10.1097/GME.0000000000000127

Loncar, 2010, Relationship between RANKL and neuroendocrine activation in elderly males with heart failure, Endocrine, 37, 148, 10.1007/s12020-009-9282-z

Mohammadpour, 2012, Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: a pilot study, Thrombosis, 10.1155/2012/306263

Secchiero, 2009, Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction, PLoS One, 4, 10.1371/journal.pone.0004442

Niessner, 2009, Prognostic value of apoptosis markers in advanced heart failure patients, Eur Heart J, 30, 789, 10.1093/eurheartj/ehp004

Mori, 2010, Association of serum TRAIL level with coronary artery disease, Thromb Res, 125, 322, 10.1016/j.thromres.2009.11.024

Volpato, 2011, Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults, Atherosclerosis, 215, 452, 10.1016/j.atherosclerosis.2010.11.004

Kawano, 2011, Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus, Diabetes Res Clin Pract, 91, 316, 10.1016/j.diabres.2010.11.034

Galeone, 2013, Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand, Int J Cardiol, 169, 296, 10.1016/j.ijcard.2013.09.012

Wu, 2013, Vascular calcification: an update on mechanisms and challenges in treatment, Calcif Tissue Int, 93, 365, 10.1007/s00223-013-9712-z

Bolon, 2002, Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis, Cell Mol Life Sci, 59, 1569, 10.1007/s00018-002-8530-7

Fernández-González, 2015, Recombinant osteoprotegerin effects during orthodontic movement in a rat model, Eur J Orthod, 10.1093/ejo/cjv056

Yao, 2011, Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs, J Oral Maxillofac Surg, 69, e446, 10.1016/j.joms.2011.07.002

Miyazaki, 2014, A review of denosumab for the treatment of osteoporosis, Patient Prefer Adherence, 8, 463, 10.2147/PPA.S46192

Suresh, 2015, Denosumab: a novel antiresorptive drug for osteoporosis, Cleve Clin J Med, 82, 105, 10.3949/ccjm.82a.13173

Kostenuik, 2009, Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL, J Bone Miner Res, 24, 182, 10.1359/jbmr.081112

Helas, 2009, Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice, Am J Pathol, 175, 473, 10.2353/ajpath.2009.080957

Samelson, 2014, RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk, J Bone Miner Res, 29, 450, 10.1002/jbmr.2043

Liu, 2014, TRAIL protects against endothelium injury in diabetes via Akt-eNOS signaling, Atherosclerosis, 237, 718, 10.1016/j.atherosclerosis.2014.10.013

Boskey, 2003, Bone mineral crystal size, Osteoporos Int, 14, S16, 10.1007/s00198-003-1468-2

Persy, 2006, Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels?, Kidney Int, 70, 1537, 10.1038/sj.ki.5001899

Nitta, 2004, Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis, Am J Kidney Dis, 44, 680, 10.1016/S0272-6386(04)00937-0

Toussaint, 2010, Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial, Am J Kidney Dis, 56, 57, 10.1053/j.ajkd.2009.12.039

Shao, 2003, Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice, J Biol Chem, 278, 50195, 10.1074/jbc.M308825200

Novaro, 2001, Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis, Circulation, 104, 2205, 10.1161/hc4301.098249

Iijima, 2014, Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification, J Atheroscler Thromb, 21, 917, 10.5551/jat.23218

Lenglet, 2014, Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis, Mediators Inflamm, 10.1155/2014/720987

Mori, 2010, Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes, Angiology, 61, 86, 10.1177/0003319708330525

Loomba, 2010, Statin therapy and aortic stenosis: a systematic review of the effects of statin therapy on aortic stenosis, Am J Ther, 17, e110, 10.1097/MJT.0b013e3181a2b1a6

Puri, 2015, Impact of statins on serial coronary calcification during atheroma progression and regression, J Am Coll Cardiol, 65, 1273, 10.1016/j.jacc.2015.01.036

Mafong, 2008, Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction, Curr Atheroscler Rep, 10, 55, 10.1007/s11883-008-0009-z

Zhan, 2014, Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway, Cardiovasc Diabetol, 13, 153, 10.1186/s12933-014-0153-4

Wu, 2003, Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells, Peptides, 24, 1149, 10.1016/j.peptides.2003.07.008

Essalihi, 2004, Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin?, J Cardiovasc Pharmacol, 44, S147, 10.1097/01.fjc.0000166250.81733.a5

Awan, 2015, Reducing vascular calcification by anti-IL-1β monoclonal antibody in a mouse model of familial hypercholesterolemia, Angiology

Davenport, 2015, The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes, Eur J Endocrinol, 173, 53, 10.1530/EJE-14-1137

Jamal, 2013, Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis, Lancet, 382, 1268, 10.1016/S0140-6736(13)60897-1

Jung, 2012, Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats, J Hypertens, 30, 2182, 10.1097/HJH.0b013e328357c049

Raggi, 2011, The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis, Nephrol Dial Transplant, 26, 1327, 10.1093/ndt/gfq725

Rodriguez, 2008, Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease, Kidney Int Suppl, S50, 10.1038/ki.2008.546

Lau, 2012, Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet, Kidney Int, 82, 1261, 10.1038/ki.2012.322

Shea, 2009, Vitamin K supplementation and progression of coronary artery calcium in older men and women, Am J Clin Neutr, 89, 1799, 10.3945/ajcn.2008.27338

Spronk, 2003, Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats, J Vasc Res, 40, 531, 10.1159/000075344

Auriemma, 2011, Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature, Am J Clin Dermatol, 12, 339, 10.2165/11587060-000000000-00000

Mathews, 2011, Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy, Am J Nephrol, 33, 131, 10.1159/000323550

Pasch, 2008, Sodium thiosulfate prevents vascular calcifications in uremic rats, Kidney Int, 74, 10.1038/ki.2008.455